PNC-27 Protocol
Dosing & Research
Last Updated: April 22, 2026
Also known as: p53-Derived Peptide, Death-Inducing Peptide, Anti-Cancer Peptide
Cancer cell apoptosis induction, Bcl-2 family protein inhibition, p53-mutant cancer models, Mitochondrial apoptosis research
Half-Life
Not Well Characterized In Vivo
Administration
Injection
Frequency
N/A
How It Works
- Synthetic 27-amino acid peptide from p53 transactivation domain. Directly inhibits anti-apoptotic proteins (Bcl-2/Bcl-xL) in cancer cells.
- Cancer cell apoptosis induction
- Bcl-2 family protein inhibition
- p53-mutant cancer models
- Mitochondrial apoptosis research
Dosing Structure
Dose
Preclinical research only
Frequency
N/A
Notes
Preclinical Studies Show Selectivity For Cancer Cells Over Normal Cells. No Human Dosing Established.
Example Protocols
Dose: Preclinical research only
Frequency: N/A
Duration: N/A
Off Period: Not listed
Protocol Notes
•
Preclinical studies show selectivity for cancer cells over normal cells.
•
No human dosing established.
Research & Studies
Loading citations…
Research Feedback
0 approved
For research discussion only. Community feedback is moderated and shown here as aggregated insights after approval.
Be the first to submit research feedback for this peptide.
Approved submissions will appear here as aggregated insights.